They postulated that KRAS mutation in NSCLC might be associated with a favorable response to ICI therapy in the absence of a concurrent mutation in the STK11 and/or KEAP1 tumor suppressor genes (10). The gene discussed is STK11; the disease is non-small cell lung carcinoma.